1. Search Result
Search Result
Results for "

intercellular junction

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Peptides

2

MCE Kits

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148033

    N,N,N-Trimethylchitosan

    Drug Derivative Others
    Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .
    Trimethyl chitosan
  • HY-W010653

    lrganox 1010; AT1010

    Environmental Pollutants Biochemical Assay Reagents Others
    Antioxidant 1010 (lrganox 1010; AT1010) is a hindered phenolic antioxidant. Antioxidant 1010 does not inhibit intercellular gap-junctional communication. Antioxidant 1010 exhibits antioxidant efficacy in plastic, rubber and synthetic fiber .
    Antioxidant 1010
  • HY-B0327
    Irsogladine
    3 Publications Verification

    Dicloguamine

    Phosphodiesterase (PDE) NF-κB AP-1 TRP Channel Interleukin Related Inflammation/Immunology Cancer
    Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
    Irsogladine
  • HY-159069

    Toll-like Receptor (TLR) TNF Receptor Connexin Infection Cancer
    Zymosan (ZM), 95% is a yeast cell wall-derived carbohydrate-rich preparation and immunomodulator. Zymosan (ZM), 95% binds to and activates TLR-2, TLR-4, and Dectin-1 receptor to trigger downstream signaling pathways. Zymosan (ZM), 95% upregulates TLR-2, TLR-4, and TNF-α mRNA expression, increases serum TNF-α levels, and stimulates splenocyte number and viability in mice. Zymosan (ZM), 95% attenuates melanoma growth progression, modulates macrophage marker gene expression, and mediates phagocytosis, ROS generation, and cytokine production. Zymosan (ZM), 95% reduces Connexin 43 protein and mRNA levels, inhibits gap junctional intercellular communication, and induces proinflammatory factor production in human corneal cells. Zymosan (ZM), 95% induces peritoneal inflammation in mice, functions as a drug carrier, and supports fibroblast cell attachment in hydrogel formulations. Zymosan (ZM), 95% can be used for the research of melanoma, tumors, fungal keratitis, ocular surface inflammatory disorders, and peritoneal inflammation .
    Zymosan (ZM), 95%
  • HY-P11197

    Gap Junction Protein Cancer
    ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen (HY-13757A) and Lapatinib (HY-50898) in breast cancer. ACT1 can be used for breast cancer research .
    ACT1
  • HY-P11154

    Ac-SHAVSS-NH2

    Cadherin Others
    HAV peptide (Ac-SHAVSS-NH2) is a peptide containing His-Ala-Val. HAV peptide affects the E-cadherin signaling pathway. HAV peptide regulates intercellular junctions .
    HAV peptide
  • HY-W010653R

    lrganox 1010 (Standard); AT1010 (Standard)

    Reference Standards Biochemical Assay Reagents Others
    Antioxidant 1010 (Standard) is the analytical standard of Antioxidant 1010 (lrganox 1010; AT1010) (HY-W010653) . This product is intended for research and analytical applications. Antioxidant 1010 is a hindered phenolic antioxidant. Antioxidant 1010 does not inhibit intercellular gap-junctional communication. Antioxidant 1010 exhibits antioxidant efficacy in plastic, rubber and synthetic fiber ..
    Antioxidant 1010 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: